MBX Biosciences (MBX) Retained Earnings (2023 - 2026)

MBX Biosciences has reported Retained Earnings for 4 years, with the latest figure at -$248.0 million in Q1 2026.

• Quarterly Retained Earnings fell 53.67% year-over-year to -$248.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.0 million (down 53.67% YoY) and the FY2025 annual result came in at $286000.0, up 420.0% from the prior year.
• Retained Earnings retreated to -$248.0 million in Q1 2026 per MBX's latest filing, from $286000.0 in the prior quarter.
• Over five years, Retained Earnings peaked at $286000.0 in Q4 2025 and troughed at -$248.0 million in Q1 2026.
• A 4-year average of -$88.9 million and a median of -$60.9 million in 2024 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings surged 420.0% in 2025, then tumbled 53.67% in 2026.
• Over 4 years, Retained Earnings stood at $60000.0 in 2023, then fell by 8.33% to $55000.0 in 2024, then soared by 420.0% to $286000.0 in 2025, then sank by 86813.29% to -$248.0 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$248.0 million, $286000.0, and $154000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.